An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
BYOMass Announces Appointment of Drs. Declan Doogan and Stephen Hoffman to Board of Directors
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary
BYOMass has appointed Dr. Declan Doogan and Dr. Stephen Hoffman to its Board of Directors. Dr. Doogan, a pharmaceutical veteran, previously led drug development at Pfizer and was Head of R&D at Amarin Corporation. Dr. Hoffman brings extensive experience from Aerpio Pharmaceuticals and has served on multiple biotech boards. Their expertise is expected to guide BYOMass’s innovative pipeline targeting the TGF-β superfamily, potentially improving therapies for diseases with high unmet medical needs.
Positive
Appointment of experienced board members, enhancing leadership expertise.
Potential to advance innovative therapies targeting TGF-β superfamily for unmet medical needs.
Negative
None.
BOSTON--(BUSINESS WIRE)--
BYOMass, Inc., a biotech company developing selective TGF-β superfamily therapeutics, today announced the appointment of Declan Doogan, M.D., and Stephen Hoffman, M.D., Ph.D., to the company’s Board of Directors. Dr. Doogan has more than 30 years of experience in the global pharmaceutical industry, and is the Chief Medical Officer and Cofounder of Juvenescence. Dr. Hoffman has more than 30 years of experience in founding, leading, and advising biotech companies advancing innovative therapeutic pipelines.
“As biotech cofounders, executive leaders, and expert drug developers, Drs. Doogan and Hoffman have extensive experience in building biotech companies, guiding innovation, and developing therapies from early-stage research through commercialization,” said V. Margaret Jackson, D.Phil., Founder and Chief Executive Officer of BYOMass, Inc. “Their significant insights will be invaluable to us as we advance novel biologics and small molecules to target the TGF-β superfamily, a significant biological pathway involved in numerous diseases and disorders without effective therapies.”
“The members of the TGF-β superfamily are master regulators of a wide range of physiological processes, including tissue morphogenesis, tissue repair, hematopoiesis, immunoregulation and reproductive function,” said Dr. Doogan. “With the safety concerns involved in inhibiting TGF-β directly or blocking pathway receptors, the team at BYOMass has established a unique approach to selectively targeting specific members and pathways within the TGF-β superfamily that has the potential to treat a range of diseases and disorders.”
“BYOMass has internally developed a pathway-driven pipeline of novel biologics and first-in-class small molecules selective targeting TGF-β superfamily members that have the potential to offer safe and effective therapeutics for orphan and common diseases of high unmet medical need,” said Dr. Hoffman. “Furthermore, the team is pioneering a precision medicine approach to clinical development by identifying patient populations where specific TGF-β superfamily members play a major role in their disease.”
In addition to his role at Juvenescence, Dr. Doogan is the Chairman and Cofounder of Biohaven Pharmaceuticals, Portage Biotech, and PH Precision Med, and a visiting professor at Glasgow University. Previously, Dr. Doogan was Head of Worldwide Drug Development at Pfizer, where he worked in the US, UK, and Japan. Previously, he was also Head of R&D at Amarin Corporation. Dr. Doogan earned his M.D. from Glasgow University, and he is a Fellow of the Royal College of Physicians and Surgeons of Glasgow.
Dr. Hoffman most recently served as CEO of Aerpio Pharmaceuticals and prior to that was a senior advisor to PDL BioPharma, a General Partner at TVM Capital and a Managing Director at Skyline Ventures. Before his positions in venture capital, Dr. Hoffman served as President, CEO, and a member of the board of directors of Allos Therapeutics, where he remained as Chairman of the Board until it was acquired by Spectrum Pharmaceuticals. Dr. Hoffman currently serves on the Boards of Directors of AcelRx Pharmaceuticals, Dicerna Pharmaceuticals, Danforth Advisors, and Apic Bio.
About BYOMass
BYOMass is a preclinical pharmaceutical company developing novel biologic and small molecule drugs to modulate specific members of the TGF-β superfamily, for the treatment of orphan and common diseases of high unmet medical need. Selectively targeting specific members and pathways within the TGF-β superfamily has the potential to be a meaningful class of therapeutics within oncology, inflammatory/immune, fibrotic, and metabolic diseases. For more information, please visit www.byomasstx.com.
What is the significance of the new board members at BYOMass?
The addition of Dr. Doogan and Dr. Hoffman brings over 60 years of combined experience in drug development and biotech leadership, which may enhance BYOMass's strategic direction.
What are the backgrounds of Dr. Declan Doogan and Dr. Stephen Hoffman?
Dr. Doogan has extensive experience in pharmaceutical development, having worked at Pfizer and Amarin, while Dr. Hoffman has led multiple biotech companies and served on several boards.
How might the new board members impact BYOMass's stock performance?
Their expertise could strengthen the company's innovative pipeline, potentially leading to increased investor confidence and improved stock performance.
